Bengamide B

Bengamide B is an alkaloid with anti-tumor and anti-inflammatory activities. Bengamide B reduces the phosphorylation level of IκBα, thereby blocking the activation of NF-κB. Bengamide B inhibits the proliferation of tumor cells. Bengamide B can be used in research related to inflammatory diseases and cancers^[1][2]. In Vitro:Bengamide B (18 h) potently inhibits NF-κB activity in RAW264.7 cells with an IC₅₀ of 0.085 μM; it shows no cytotoxicity against RAW264.7 cells at concentrations up to 50 μM; it also potently inhibits the growth of HCT-116 cells with an IC₅₀ of 0.002 μM^[1].
Bengamide B (0-10 μM; 4 h) dose-dependently inhibits LPS (HY-D1056)-induced phosphorylation of IκBα in RAW264.7 cells^[1].
Bengamide B (0.01-10 μM) dose-dependently inhibits LPS-induced expression of TNFα, IL-6 and MCP-1 in RAW264.7 cells^[1].
Bengamide B (3 days) potently inhibits the proliferation of MDA-MB-435 human breast cancer cells in vitro, with an IC₅₀ value of 0.0024 μM^[2]. In Vivo:Bengamide B (10-33 µmol/kg; intravenous injection; three times per week; for 3 consecutive weeks) exerts statistically significant, dose-dependent inhibitory effects on the growth of MDA-MB-435 breast cancer xenografts in athymic nude mice^[2].